HRP20211802T1 - Pripravak za kontroliranu stimulaciju jajnika - Google Patents

Pripravak za kontroliranu stimulaciju jajnika Download PDF

Info

Publication number
HRP20211802T1
HRP20211802T1 HRP20211802TT HRP20211802T HRP20211802T1 HR P20211802 T1 HRP20211802 T1 HR P20211802T1 HR P20211802T T HRP20211802T T HR P20211802TT HR P20211802 T HRP20211802 T HR P20211802T HR P20211802 T1 HRP20211802 T1 HR P20211802T1
Authority
HR
Croatia
Prior art keywords
amh
patient
pmol
body weight
treatment
Prior art date
Application number
HRP20211802TT
Other languages
English (en)
Croatian (hr)
Inventor
Joan-Carles ARCE SAEZ
Lisbeth HELMGAARD
Bjarke Mirner Klein
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of HRP20211802T1 publication Critical patent/HRP20211802T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20211802TT 2017-09-01 2018-08-31 Pripravak za kontroliranu stimulaciju jajnika HRP20211802T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
EP18768795.9A EP3675894B1 (en) 2017-09-01 2018-08-31 Composition for controlled ovarian stimulation
PCT/EP2018/073442 WO2019043143A1 (en) 2017-09-01 2018-08-31 COMPOSITION FOR CONTROLLED OVARIAN STIMULATION

Publications (1)

Publication Number Publication Date
HRP20211802T1 true HRP20211802T1 (hr) 2022-03-04

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20211802TT HRP20211802T1 (hr) 2017-09-01 2018-08-31 Pripravak za kontroliranu stimulaciju jajnika
HRP20241171TT HRP20241171T1 (hr) 2017-09-01 2018-08-31 Pripravak za kontroliranu stimulaciju jajnika

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20241171TT HRP20241171T1 (hr) 2017-09-01 2018-08-31 Pripravak za kontroliranu stimulaciju jajnika

Country Status (32)

Country Link
US (2) US11744879B2 (enExample)
EP (3) EP3973982B1 (enExample)
JP (2) JP6856819B2 (enExample)
KR (2) KR20250078595A (enExample)
CN (2) CN120617484A (enExample)
AR (1) AR112541A1 (enExample)
AU (1) AU2018326556B2 (enExample)
BR (1) BR112020003379A2 (enExample)
CA (1) CA3073624A1 (enExample)
CL (1) CL2020000482A1 (enExample)
DK (2) DK3675894T3 (enExample)
EA (1) EA202090480A1 (enExample)
ES (2) ES2904787T3 (enExample)
FI (1) FI3973982T3 (enExample)
HR (2) HRP20211802T1 (enExample)
HU (2) HUE068024T2 (enExample)
IL (1) IL272763B2 (enExample)
JO (1) JOP20200034A1 (enExample)
LT (2) LT3973982T (enExample)
MA (2) MA50034B1 (enExample)
MD (2) MD3973982T2 (enExample)
MX (2) MX2020002235A (enExample)
MY (1) MY200791A (enExample)
PH (1) PH12020500404A1 (enExample)
PL (2) PL3973982T3 (enExample)
PT (2) PT3675894T (enExample)
RS (2) RS62810B1 (enExample)
SG (1) SG11202003840QA (enExample)
SI (2) SI3973982T1 (enExample)
TW (1) TWI749255B (enExample)
UA (1) UA126869C2 (enExample)
WO (1) WO2019043143A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE267608T1 (de) * 2000-01-27 2004-06-15 Applied Research Systems Verwendung von fsh zur behandlung von infertilität
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (en) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comprising mucilaginous polysaccharides derived from aloe barbadensis combined with liposomes, method for obtaining same and use thereof as a sun protector, an anti-acne agent, an epidermal regenerator and a moisturiser
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
CA2945883A1 (en) * 2014-04-18 2015-10-22 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
MD3261661T2 (ro) 2015-02-26 2024-04-30 Ferring Bv Menotropină pentru tratarea infertilității
HUE048757T2 (hu) * 2015-04-17 2020-08-28 Ferring Bv FSH meddõség kezelésére
EP3286209B1 (en) 2015-04-24 2020-11-25 Ferring BV Method of production of gonadotrophin
AU2016282916B2 (en) 2015-06-26 2022-01-20 Ferring B.V. Methods of purification and/or viral inactivation
PL3787667T3 (pl) 2018-04-30 2025-07-28 Ferring B.V. Kompozycja do kontrolowanej stymulacji jajników
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法

Also Published As

Publication number Publication date
US20240024424A1 (en) 2024-01-25
IL272763B2 (en) 2024-02-01
CN111050787A (zh) 2020-04-21
PL3973982T3 (pl) 2024-11-04
AR112541A1 (es) 2019-11-06
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
EP4427806A2 (en) 2024-09-11
SG11202003840QA (en) 2020-05-28
RS65945B1 (sr) 2024-10-31
UA126869C2 (uk) 2023-02-15
FI3973982T3 (fi) 2024-09-23
CN120617484A (zh) 2025-09-12
JP2021046398A (ja) 2021-03-25
KR20250078595A (ko) 2025-06-02
HUE056726T2 (hu) 2022-03-28
DK3973982T3 (da) 2024-09-23
HUE068024T2 (hu) 2024-12-28
SI3973982T1 (sl) 2024-10-30
MA56224B1 (fr) 2024-09-30
MX2024009224A (es) 2024-08-06
PT3675894T (pt) 2022-01-25
MA50034B1 (fr) 2022-02-28
PT3973982T (pt) 2024-09-16
MA50034A (fr) 2021-05-12
LT3973982T (lt) 2024-09-10
BR112020003379A2 (pt) 2020-08-25
SI3675894T1 (sl) 2022-01-31
EP4427806A3 (en) 2024-10-09
IL272763A (en) 2020-04-30
ES2989511T3 (es) 2024-11-26
TWI749255B (zh) 2021-12-11
CL2020000482A1 (es) 2020-06-26
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
EP3973982A1 (en) 2022-03-30
US20200197493A1 (en) 2020-06-25
US11744879B2 (en) 2023-09-05
EP3973982B1 (en) 2024-07-31
WO2019043143A1 (en) 2019-03-07
MY200791A (en) 2024-01-16
JP2020528071A (ja) 2020-09-17
MD3973982T2 (ro) 2024-11-30
AU2018326556A1 (en) 2020-03-05
MX2020002235A (es) 2020-07-20
AU2018326556B2 (en) 2024-09-26
TW201919687A (zh) 2019-06-01
PH12020500404A1 (en) 2021-03-01
MA56224A (fr) 2022-04-20
JP7373479B2 (ja) 2023-11-02
ES2904787T3 (es) 2022-04-06
KR20200045543A (ko) 2020-05-04
EP3675894B1 (en) 2021-11-03
EP3675894A1 (en) 2020-07-08
MD3675894T2 (ro) 2022-03-31
CA3073624A1 (en) 2019-03-07
JOP20200034A1 (ar) 2020-02-13
HRP20241171T1 (hr) 2024-11-22
DK3675894T3 (da) 2022-01-24
RS62810B1 (sr) 2022-02-28
JP6856819B2 (ja) 2021-04-14

Similar Documents

Publication Publication Date Title
HRP20230607T1 (hr) Pripravak za kontroliranu stimulaciju jajnika
BR112021024137A2 (pt) Dispositivos e métodos para entrega de dose com precisão
HRP20240013T1 (hr) Menotropin za liječenje neplodnosti
MY188749A (en) Compositions comprising a combination of nivolumab and ipilimumab
MX2016016406A (es) Estructuras de permanencia, y métodos relacionados.
BR112017025752A2 (pt) dispositivo de aplicação de fármaco
HRP20211802T1 (hr) Pripravak za kontroliranu stimulaciju jajnika
WO2018089706A3 (en) Activin receptor type iia variants and methods of use thereof
MX2019006189A (es) Regeneracion osea dirigida a una fractura mediante estimulacion del receptor de la hormona paratiroidea.
BR0210630A (pt) Sistema fornecedor de liberação prolongada
EA201992612A1 (ru) Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
BR112019008021A2 (pt) métodos de distribuição de um polipeptídeo neuroprotetor ao sistema nervoso central
NZ769954A (en) Syringe devices for use in an emergency
MX2019014666A (es) Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo.
BR112018000018A2 (pt) dispositivo e sistema de liberação de uso único com aspectos de segurança
BR112018000674A2 (pt) implante peniano
HRP20250052T1 (hr) Postupak liječenja multiple skleroze
JP2021046398A5 (enExample)
Morroni et al. Contraceptive implants and efavirenz-based ART: friend or foe?
WO2017168414A8 (en) Iron chelators and combination thereof for the treatment of wolfram syndrome 2
Alves et al. Human immunodeficiency virus post-exposure prophylaxis: Primum non nocere
TH2001001168A (th) องค์ประกอบสำหรับการกระตุ้นรังไข่แบบควบคุม
de Thé Lessons taught by acute promyelocytic leukemia cure
El-Battrawy et al. Psychiatric disease among patients with takotsubo syndrome
Eby The mouth–nose biologically closed electric circuit in zinc lozenge therapy of common colds as explanation of rapid therapeutic action